不同剂量PEG-rhG-CSF临床疗效、安全性和最小成本分析

The efficacy, safety and cost-minimization analysis of different doses of pegylated recombinant human granulocyte-colony stimulating factor

目的探讨不同剂量聚乙二醇化重组人粒细胞刺激因子(pegylated recombinant human granulocyte-colony stimulating factor,PEG-rhG-CSF)的临床疗效、安全性与经济性,为临床用药提供参考。方法收集2017年1月―2018年12月在中国科学技术大学附属第一医院(安徽省立医院)化疗后发生IV度骨髓抑制的恶性肿瘤患者106例。按给药剂量不同分为两组,A组(PEG-rhG-CSF 3 mg)64例,B组(PEG-rhG-CSF 6 mg)42例,比较用药前后的临床疗效、不良反应,计算治疗成本,对两组治疗方案进行药物经济学最小成本分析。结果A组(PEG-rhG-CSF 3 mg)和B组(PEG-rhG-CSF 6 mg)的临床疗效和不良反应比较,差异无统计学意义(均有P>0.05)。A组和B组治疗方案的成本分别为1705元和3410元,A组(PEG-rhG-CSF 3 mg)治疗方案更经济。结论考虑到药物的有效性和经济学,A组(PEG-rhG-CSF 3 mg)治疗方案是治疗IV度骨髓抑制的最佳治疗方案。

Objective To evaluate the efficacy,safety and economics of myelosuppression treated by different doses of pegylated recombinant human granulocyte-colony stimulating factor(PEG-rhG-CSF),so as to provide reference for clinical use.Methods 106 patients with grade IV myelosuppression after chemotherapy from January 2017 to December 2018 were collected.According to different doses,patients were divided into two groups:64 cases in group A(PEG-rhG-CSF 3 mg)and 42 cases in group B(PEG-rhG-CSF 6 mg).Clinical efficacy and adverse reactions were compared,and treatment cost was calculated so that cost-minimization analysis in pharmacoeconomic was compared between the two groups.Results There was no significant difference in clinical efficacy and adverse reactions between group A and group B(all P>0.05).The cost of these two regimens was RMB 1705 for group A and RMB 3410 for group B.The regimen in group A was more economical.Conclusions The regimen in group A(PEG-rhG-CSF 3 mg)is the proper option for grade IV myelosuppression in China,considering the efficacy,safety,and cost-minimization analysis of the drug.